No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BSX Boston Scientific
- 76.760
- -0.200-0.26%
Close Jun 14 16:00 ET
- 77.179
- +0.419+0.55%
Post 19:47 ET
112.85BMarket Cap64.50P/E (TTM)
77.030High76.430Low3.54MVolume76.850Open76.960Pre Close271.81MTurnover0.24%Turnover Ratio71.74P/E (Static)1.47BShares77.64052wk High5.66P/B112.50BFloat Cap48.35052wk Low--Dividend TTM1.47BShs Float77.640Historical High--Div YieldTTM0.78%Amplitude4.790Historical Low76.771Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
3 Reasons to Hold Veeva Systems (VEEV) Stock in Your Portfolio
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention.Investors are constantly o
McKesson (MCK) Gains 26% YTD: What's Driving the Rally?
DaVita (DVA) Gains 36% YTD: What's Driving the Stock Rally?
Boston Scientific (BSX) Ascends But Remains Behind Market: Some Facts to Note
Here's Why You Should Retain Integer Holdings (ITGR) Stock
Comments
$Boston Scientific(BSX.US$
NEWS
MODULAR ATP Study of the mCRM™ System Meets Primary Safety and Efficacy Endpoints
Positive
MODULAR ATP study met all safety and efficacy endpoints.
Major complication-free rate of 97.5% for EMPOWER LP.
Communication success rate of 98.8% between EMBLEM S-ICD and EMPOWER LP.
ATP success rate of 61.3% with no patient therapy deactivations due to discomfort.
Pacing capture thresholds met in 97.4% of patients.
Positive clinical performance suggests a potential upgrad...
NEWS
MODULAR ATP Study of the mCRM™ System Meets Primary Safety and Efficacy Endpoints
Positive
MODULAR ATP study met all safety and efficacy endpoints.
Major complication-free rate of 97.5% for EMPOWER LP.
Communication success rate of 98.8% between EMBLEM S-ICD and EMPOWER LP.
ATP success rate of 61.3% with no patient therapy deactivations due to discomfort.
Pacing capture thresholds met in 97.4% of patients.
Positive clinical performance suggests a potential upgrad...
ColumnsOptions Market Statistics: Tesla Stock Jumps on Accelerated Production Plans Despite Earnings Miss
News Highlights
$Tesla(TSLA.US$ shares rose by 1.85%, closing at $144.68. Its options trading volume was 1.75 million. Call contracts account for 44.8% of the total trading volume. The most traded calls are contracts of $160 strike price that expire on Apr. 26th. The total volume reaches 48,736 with an open interest of 28,774. The most traded puts are contracts of a $140 strike price that expires o...
$Tesla(TSLA.US$ shares rose by 1.85%, closing at $144.68. Its options trading volume was 1.75 million. Call contracts account for 44.8% of the total trading volume. The most traded calls are contracts of $160 strike price that expire on Apr. 26th. The total volume reaches 48,736 with an open interest of 28,774. The most traded puts are contracts of a $140 strike price that expires o...
24
3
Insiders selling Boston Scientific shares, even below current price, is discouraging. Yet, high insider ownership could imply company's interest in all shareholders.
1
Boston Scientific's high P/E ratio is attributed to investors' optimism about its strong future growth and market outperformance. Shareholders' confidence in the company's future earnings supports the current P/E ratio and share price.
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg